| Mitochondrial patch clamp of beige adipocytes reveals UCP1-positive and UCP1-negative cells both exhibiting futile creatine cycling AM Bertholet, L Kazak, ET Chouchani, MG Bogaczyńska, I Paranjpe, ... Cell metabolism 25 (4), 811-822. e4, 2017 | 235 | 2017 |
| Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice DB Dubal, L Zhu, PE Sanchez, K Worden, L Broestl, E Johnson, K Ho, ... Journal of Neuroscience 35 (6), 2358-2371, 2015 | 221 | 2015 |
| Transient activation of the CA3 Kappa opioid system in the dorsal hippocampus modulates complex memory processing in mice S Daumas, A Betourne, H Halley, DP Wolfer, HP Lipp, JM Lassalle, ... Neurobiology of learning and memory 88 (1), 94-103, 2007 | 58 | 2007 |
| A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson’s disease M Szelechowski, A Bétourné, Y Monnet, CA Ferré, A Thouard, C Foret, ... Nature communications 5 (1), 5181, 2014 | 57 | 2014 |
| Protein kinase C inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania E Abrial, A Bétourné, A Etiévant, G Lucas, H Scarna, L Lambás-Señas, ... International Journal of Neuropsychopharmacology 18 (2), pyu031, 2015 | 54 | 2015 |
| A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice S Marchand, A Betourne, V Marty, S Daumas, H Halley, JM Lassalle, ... Peptides 27 (5), 964-972, 2006 | 53 | 2006 |
| β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS) RT Bartus, A Bétourné, A Basile, BL Peterson, J Glass, NM Boulis Neurobiology of disease 85, 11-24, 2016 | 47 | 2016 |
| Involvement of hippocampal CA3 KATP channels in contextual memory A Betourne, AM Bertholet, E Labroue, H Halley, HS Sun, A Lorsignol, ... Neuropharmacology 56 (3), 615-625, 2009 | 45 | 2009 |
| Borna disease virus phosphoprotein modulates epigenetic signaling in neurons to control viral replication EM Bonnaud, M Szelechowski, A Bétourné, C Foret, A Thouard, ... Journal of Virology 89 (11), 5996-6008, 2015 | 31 | 2015 |
| Decreased motivational properties of morphine in mouse models of cancerous-or inflammatory-chronic pain: implication of supraspinal neuropeptide FF2 receptors A Betourne, J Familiades, L Lacassagne, H Halley, M Cazales, ... Neuroscience 157 (1), 12-21, 2008 | 26 | 2008 |
| The M1311V variant of ATP7A is associated with impaired trafficking and copper homeostasis in models of motor neuron disease N Bakkar, A Starr, BE Rabichow, I Lorenzini, ZT McEachin, R Kraft, ... Neurobiology of disease 149, 105228, 2021 | 21 | 2021 |
| Hippocampal expression of a virus-derived protein impairs memory in mice A Betourne, M Szelechowski, A Thouard, E Abrial, A Jean, F Zaidi, C Foret, ... Proceedings of the National Academy of Sciences 115 (7), 1611-1616, 2018 | 19 | 2018 |
| HSPA9/Mortalin mediates axo-protection and modulates mitochondrial dynamics in neurons CA Ferré, A Thouard, A Bétourné, AL Le Dorze, P Belenguer, MC Miquel, ... Scientific reports 11 (1), 17705, 2021 | 15 | 2021 |
| 321; Development of Intrathecal Riluzole: A New Route of Administration for the Treatment of Amyotrophic Lateral Sclerosis Patients J Gutierrez, T Federici, B Peterson, R Bartus, A Betourne, NM Boulis Neurosurgery 63, 193, 2016 | 13 | 2016 |
| Central locomotor and cognitive effects of a NPFF receptor agonist in mouse A Betourne, V Marty, J Ceccom, H Halley, JM Lassalle, JM Zajac, ... Peptides 31 (2), 221-226, 2010 | 13 | 2010 |
| Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery SK Gross, BS Shim, RT Bartus, D Deaver, Z McEachin, A Bétourné, ... Experimental Neurology 323, 113091, 2020 | 11 | 2020 |
| The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP) JS Barrett, A Betourne, RL Walls, K Lasater, S Russell, A Borens, ... Journal of Pharmacokinetics and Pharmacodynamics 50 (6), 507-519, 2023 | 9 | 2023 |
| Innovations in therapy development for rare diseases through the rare disease cures accelerator-data and analytics platform J Larkindale, A Betourne, A Borens, V Boulanger, V Theurer Crider, ... Therapeutic Innovation & Regulatory Science 56 (5), 768-776, 2022 | 9 | 2022 |
| Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) best practices and recommendations for FAIR data, toward alignment with International Regulatory agencies A Bétourné, RL Walls, A Bateman-House, C Ollivier, H Huynh, D Olson, ... Critical Path Institute, 2022 | 3 | 2022 |
| Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases D Dunia, M Szelechowski, A Betourne, S Hunot US Patent 10,059,748, 2018 | 3 | 2018 |
Bernard FrancésProfesseur de neurosciences, Université de Toulouse在 univ-tlse3.fr 的电子邮件经过验证
